

Scott Lindhorst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3154519/publications.pdf>

Version: 2024-02-01

23
papers

1,898
citations

840776

11
h-index

794594

19
g-index

25
all docs

25
docs citations

25
times ranked

4269
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	30.7	53
2	Case report: Awake craniotomy during pregnancy for resection of glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2022, 216, 107218.	1.4	4
3	IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study. <i>Neuro-Oncology</i> , 2022, 24, i84-i84.	1.2	1
4	Seizures in Patients With Metastatic Brain Tumors: Prevalence, Clinical Characteristics, and Features on EEG. <i>Journal of Clinical Neurophysiology</i> , 2021, 38, 143-148.	1.7	12
5	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
6	Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth. <i>Clinical and Translational Oncology</i> , 2020, 22, 1138-1145.	2.4	21
7	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. <i>Acta Neuropathologica</i> , 2020, 140, 765-776.	7.7	23
8	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	1.2	19
9	Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations. <i>Clinical and Translational Oncology</i> , 2020, 22, 2017-2025.	2.4	15
10	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii363-iii363.	1.2	1
11	RARE-17. SURVIVAL BENEFIT FOR INDIVIDUALS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME AND BRAIN TUMORS WHO UNDERGO SURVEILLANCE PROTOCOL. A REPORT FROM THE INTERNATIONAL REPLICATION REPAIR CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii445-iii446.	1.2	0
12	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii347-iii348.	1.2	0
13	CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539. <i>Neuro-Oncology</i> , 2020, 22, ii55-ii56.	1.2	4
14	Clinical characteristics, EEG findings and implications of status epilepticus in patients with brain metastases. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116538.	0.6	2
15	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, ii96-ii97.	1.2	0
16	Seizures in patents with primary central nervous system lymphoma: Prevalence and associated features. <i>Journal of the Neurological Sciences</i> , 2019, 400, 34-38.	0.6	10
17	EXTH-48. GALECTIN-1 INHIBITION SENSITIZES RADIATION TREATMENT IN A PRE-CLINICAL MODEL OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi92-vi92.	1.2	1
18	EXTH-29. GALECTIN-3 AS A POTENTIAL THERAPEUTIC TARGET IN RECURRENT ATYPICAL AND MALIGNANT MENINGIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi88-vi88.	1.2	0

#	ARTICLE	IF	CITATIONS
19	ACTR-32. NRG ONCOLOGY RTOG 1205: RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VS. BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi20-vi20.	1.2	11
20	HGG-20. DNA METHYLATION ANALYSIS OF HIGH-GRADE GLIOMA IN PATIENTS WITH MISMATCH REPAIR DEFICIENCIES. <i>Neuro-Oncology</i> , 2018, 20, i92-i93.	1.2	0
21	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
22	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
23	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	1.6	692